Fibrinopeptide A (FPA) is a very sensitive marker of fibrin generation in vivo. Because an imbalance between thrombogenic and thrombolytic forces may be responsible for the failure to recanalize and for reocclusion of coronary arteries, such a marker could be of eminent value during thrombolytic treatment of acute myocardial infarction. Thirty-four consecutive patients with acute myocardial infarction (peak creatine kinase level, 1,869±+1,543 IU/l) were treated with 100 mg recombinant tissue-type plasminogen activator (rt-PA) 3.1±1.1 hours after onset of chest pain. Angiography 12.5+±6.1 days later revealed an 81% patency rate of the infarct-related vessel. FPA plasma levels (normal, 1.9±0.5 ng/ml) were 34±46 ng/ml on admission and 93+86 ng/ml (538 ±674% with respect to each patient's admission level) after 90 minutes of rt-PA infusion (p <0.01). In patients without evidence of reocclusion (including three primary failures), FPA levels fell under continuous heparin infusion to 6.7 +9.7 ng/ml (24+33%,p<O.O1) within 30 minutes and were 3.1+2.2 ng/ml (15+1±%,p<O0.01), 1.6+1.1 ng/ ml (8±10%, p<0.01), and 2.5± 3.0 ng/ml (12±f 16%, p<0.01) 30 minutes, 9 hours, and 21 hours, respectively, after completion of rt-PA therapy. Five patients sustained intermittent or permanent coronary reocclusion after primary thrombolytic success. Their early postlytic FPA levels (13-51 ng/ml) remained high or increased again despite adequate anticoagulation. FPA allows the monitoring of fibrin generation during acute myocardial infarction and thrombolytic therapy. Despite successful recanalization, fibrin generation is increased under rt-PA administration before anticoagulation. Patients under anticoagulation with postlytic FPA levels less than 5 ng/ml or below their admission value seem to be at low risk of reocclusion for several days. FPA levels that are persistently high or that increase again despite adequate anticoagulation indicate ongoing fibrin generation. However, whether FPA can indeed be considered a useful marker of reocclusion remains to be confirmed in a larger population of patients with acute myocardial infarction. (Circulation 1989;79:980-989) F ibrin generation is initiated by the thrombininduced cleavage of fibrinopeptide A and B (FPA and FPB) from the amino termini of fibrinogen's a-and 83-chains.' FPA is thereby released at a much faster rate, whereas most of FPB is cleaved off after polymerization only.2 The possibility of specific measurements by radioimmunoassay3-7 made FPA a very sensitive marker of fibrin generation in vivo. Elevated plasma levels of FPA have been found in patients with venous
(24+33%,p<O.O1) within 30 minutes and were 3.1+2.2 ng/ml (15+1±%,p<O0.01), 1 .6+1.1 ng/ ml (8±10%, p<0.01), and 2.5± 3.0 ng/ml (12±f 16%, p<0.01) 30 minutes, 9 hours, and 21 hours, respectively, after completion of rt-PA therapy. Five patients sustained intermittent or permanent coronary reocclusion after primary thrombolytic success. Their early postlytic FPA levels (13-51 ng/ml) remained high or increased again despite adequate anticoagulation. FPA allows the monitoring of fibrin generation during acute myocardial infarction and thrombolytic therapy. Despite successful recanalization, fibrin generation is increased under rt-PA administration before anticoagulation. Patients under anticoagulation with postlytic FPA levels less than 5 ng/ml or below their admission value seem to be at low risk of reocclusion for several days. FPA levels that are persistently high or that increase again despite adequate anticoagulation indicate ongoing fibrin generation. However, whether FPA can indeed be considered a useful marker of reocclusion remains to be confirmed in a larger population of patients with acute myocardial infarction. (Circulation 1989; 79:980-989) F ibrin generation is initiated by the thrombininduced cleavage of fibrinopeptide A and B (FPA and FPB) from the amino termini of fibrinogen's a-and 83-chains.' FPA is thereby released at a much faster rate, whereas most of FPB is cleaved off after polymerization only.2 The possibility of specific measurements by radioimmunoassay3-7 made FPA a very sensitive marker of fibrin generation in vivo. Elevated plasma levels of FPA have been found in patients with venous thrombosis and pulmonary embolism,3,5,8-10 acute myocardial infarction, [11] [12] [13] [14] [15] unstable angina pectoris16,'7 or active ischemic heart disease,18 and left ventricular thrombosis19 but not in patients with stable angina pectoris, 13, 16, 19 either at rest or after exercise-induced ischemia.20,21 A reduction or inhibition of intravascular fibrin formation by heparin during evolving myocardial infarction or pulmonary embolism can be inferred from a significant decrease of initially elevated FPA plasma levels. 12, 15, 22 A marker of ongoing thrombosis could be of eminent value during thrombolytic treatment of acute myocardial infarction, in which an imbalance between thrombogenic and fibrinolytic forces may be responsible for the failure to recanalize or the reocclusion of coronary arteries. Elevated plasma levels of crosslinked fibrin degradation products have been measured during acute myocardial infarction,23 but being derived preferentially from degradation of circulating fibrin polymers, they are not predictive of recanalization by fibrinolytic therapy.24-26 FPA plasma levels have been recently analyzed during thrombolytic therapy of myocardial infarction with streptokinase. 27 The marked increase of FPA levels under streptokinase therapy was interpreted as a paradoxic prothrombotic effect of the drug.28 Plasmin-induced fibrinogenolysis yields degradation products that include measurable fibrinopeptides.29-31 The specificity of FPA as a marker of fibrin generation must therefore be questioned in the presence of a lytic state induced by an unspecific activator of fibrinolysis.
Recombinant tissue-type plasminogen activator (rt-PA) has been recognized to be superior to intravenous streptokinase with regard to fibrin specificity and recanalization of occluded coronary arteries,32 33 but early reocclusion remains a problem. [34] [35] [36] The respective roles of the drug's short half-life, of a lacking lytic state, and of an inadequate anticoagulation or platelet inhibition for the reocclusion are so far unsettled.
We determined FPA plasma levels before, during, and after rt-PA infusion, and we examined the influence of fibrinogenolysis on FPA levels, with the hypothesis that this marker of fibrin generation may be helpful in managing patients after primary success of thrombolytic therapy. Acquisition of Plasma Samples A luer lock 18 gauge intravenous cannula was carefully placed on the patient's left arm and was used for rt-PA infusion and sampling of heparinsensitive indexes. Another intravenous cannula on the right arm allowed heparin infusion and FPA sampling. FPA samples (10 ml) were obtained 1) before rt-PA and heparin infusion, 2) 90 minutes after initiation of rt-PA infusion before heparin administration, 3) 120 minutes and 30 minutes after the initiation of rt-PA and heparin infusion, respectively, 4) 30 minutes after completion of rt-PA infusion, 5) 12 hours after initiation of rt-PA infusion, and 6) 24 hours after initiation of rt-PA infusion (samples 3-6 were obtained during continuous heparin infusion). Blood was collected into precooled sample tubes containing the following anticoagulants (for 9 ml blood): 1 
Fibrinogen and Fibrin Degradation Products
Fibrinogen was determined by the chronometric method of Clauss.39 Fibrin degradation products were determined semiquantitatively by the latex agglutination test with antibodies against fibrin degradation products (Boehringer, Mannheim, FRG).
Noninvasive Signs of Recanalization
Sudden relief of chest pain, reperfusion arrhythmias, sudden resolution of ST segment elevation, and peaking of plasma MB-creatine kinase in the first two of four samples taken 8, 12, 16, and 24 hours after onset of therapy were registered as signs but not as criteria of early recanalization, considering their limited predictive value.40-4'
Cardiac Catheterization
All patients receiving treatment underwent biplane left ventriculography and selective coronarography between 1 and 26 days after thrombolytic therapy to assess left ventricular damage, patency, residual stenosis of the infarct-related vessel, and severity of the coronary artery disease.
Statistical Analysis
A semiquantitative left ventricular salvage score comparing regional wall motion with the extent of myocardium at risk, differentiated 0% (0), 25% (1), 50% (2), 75% (3), and 100% (4) myocardial salvage.
Data are reported as mean±SD. Geometric mean values are added in the tables for not normally distributed data. Nonparametric methods were used for further statistical analysis; paired data were compared by the Wilcoxon's signed-rank test; sequential data were compared by the Friedman's and the Wilcoxon-Wilcox tests.
Results

Characteristics ofPatients
Thirty men and four women (mean age, 53.2± 10.1 years) fulfilling the selection criteria underwent thrombolytic therapy of acute myocardial infarction 3.1 ± 1.1 hours after onset of symptoms in hemodynamically stable conditions. Electrocardiographic evidence of anterior (n = 17) or inferoposterior (n = 16) transmural ischemia was present in all patients but one (patient 32).
Clinical and Angiographic Results of Thrombolytic Therapy
In 30 of 34 patients, thrombolytic therapy, blood sampling, and angiographic evaluation after 12.4± 6.2 (1-26) days could be completed. The pertinent details are compiled in Table 1 . The reasons for exclusion from further analysis were absence of infarction (patient 32), interruption of thrombolytic therapy for intubation after recurrent ventricular fibrillation (patient 4), refusal of angiography (patient 15) , and lack of early FPA levels (patient 3) Tables 2 and 3 and in Figure 1 .
FPA plasma levels from healthy young volunteers who had received anticoagulation therapy (control group B), obtained by sequential sampling from an intravenous cannula, were normal (0.6±0.1 ng/ml after 2 hours, 1.1±1.3 ng/ml after 3.5 hours, and 0.7±0.2 ng/ml after 12 hours). The initial value (9.8±11.0 ng/ml) was elevated because of the insertion of the cannula. But, even without anticoagulation for the first 90 minutes, a further increase of FPA levels by the cannula was not observed (2.1 ± 1.4 ng/ml after 1.5 hours). Sequential FPA levels in control patients treated with heparin who had stable coronary artery disease (group C), obtained from intravenous cannula during 5 hours preceding angiography, were only moderately elevated and remarkably stable.
Baseline FPA levels in patients with acute myocardial infarction 3.1 ± 1.1 hours after onset of chest pain were clearly elevated to 34±46 ng/ml with marked individual variance (see Table 3 ). After 90 minutes (60 mg) of rt-PA infusion, but before anticoagulation, FPA levels increased in all but four patients to a mean of 93±86 ng/ml (p<0.01 compared with admission value). In patients without clinical signs of reocclusion (n =25), FPA levels fell to 6.7±9.7 ng/ml (p<0.01) 30 minutes after heparin and reached the level of control patients of 3.1±2.2 ng/ml (p<0.01) 30 minutes after completion of rt-PA therapy (20 of 22 FPA and 22 of 22 tc-FPA values <5 ng/ml). FPA mean levels were 1.6±1.1 ng/ml 12 hours after onset of successful thrombolytic therapy (25 of 25 FPA and tc-FPA values <5 ng/ml) and 2.5±3.0 ng/ml 24 hours after onset of thrombolysis (22 of 25 FPA and tc-FPA values <5 ng/ml). Among the patients without clinical signs of reocclusion, a patent infarct-related artery was documented in 22 of 25 (88%). In three patients (patients 24, 27, and 29) with occluded infarct vessels considered primary failures of thrombolysis, FPA levels fell to normal under heparin infusion.
Five patients (patients 12, 18, 26, 30, and 34) had clear clinical and electrocardiographic signs of coronary reocclusion after primary success of thrombolysis (see above). Elevated FPA plasma levels (12.8-51.0 ng/ml) were found 30 minutes after completion of rt-PA infusion under heparin treatment in all of them, despite a partial thromboplastin time two times above the normal level. In three patients, initially normalized FPA under heparin treatment rose again; in two patients, FPA elevation was still impressive after 12 and 24 hours (see Figure 1 ). All patients had normal plasma levels of antithrombin III, protein C, and protein S.
If one considers the relative change of FPA levels in each patient compared with the admission value (=100%), FPA levels in patients without reocclusion increased to 439±614% under rt-PA infusion, before falling to 24±33%, 15±15%, 8+10%, and 12±16% after 30 minutes, 2 hours, 10.5 hours, and 22.5 hours, respectively, of continuous anticoagulation with heparin. In patients with clinical evidence of reocclusion, the increase of FPA levels under rt-PA infusion tended to be more pronounced (954±830%). FPA exceeding admission levels (120- Table 3 ). The correction exceeded 5 Compared with control subjects, mean plasma levels of FPA were 10-40 times higher in patients with acute myocardial infarction. Although the individual variance is remarkable, these values clearly exceed previously reported values12,15 that were measured later after onset of symptoms (6-32 hours), but these values confirm high FPA levels measured before thrombolysis with streptokinase.28 Fibrin generation seems to decrease within 6-12 hours after an acute coronary occlusion.14 No correlation could be found between FPA levels and infarct size or extent of coronary artery disease; but interestingly, FPA levels in three young patients with angiographically normal coronary arteries after acute myocardial infarction were elevated, which emphasizes the role of fibrin generation in absence of significant coronary artery disease.
FPA, rather than being a specific marker of thrombotic coronary occlusion, may also reflect fibrin generation on damaged endothelium after prolonged ischemia'6 and left ventricular,43 or venous44 thrombosis. An hours after start of therapy FIGURE 1. Plot offibrinopeptide A (FPA) plasma levels (ng/ml) in acute myocardial infarction before, during, and after thrombolytic therapy with rt-PA. o0o, patients without reocclusion (n=25, mean +SD); *, patients with reocclusion (n=5) at 45 minutes (patient 12), 4 hours (patient 34), 7 hours (patient 26), and 8 days (patient 18) and repeated during 4 hours (patient 30) after primary success of thrombolytic therapy. shown for patients with pulmonary infarction or (p<O.Ol). Compared with levels measured under streppleural effusion after pulmonary embolism,10,22 can tokinase infusion,28 the increase under rt-PA adminbe excluded, with the highest FPA levels measured istration is much less pronounced. Therefore, the very early after coronary occlusion and falling question arises of whether a crossreaction with FPAabruptly after intravenous heparin therapy.
containing peptides originating from fibrinogen degradation leads to falsely elevated FPA levels. Whether this applies to thrombolysis with a less fibrin specific agent, such as streptokinase, remains to be determined. No crossreactivity was detected in the plasma of streptokinase-treated patients by separating the large fibrinogen degradation fragments with gel chromatography; crossreactivity with a-1-20 or a-1-24 fibrinogen fragments, however, could not be excluded. 28 Thus, further fibrin generation under thrombolytic therapy must be postulated as already proposed for streptokinase28 and rt-PA. 45 Thrombin activity could be sustained by endothelial damage in the ischemic territory,16 by subendothelial collagen reexposed through thrombolysis, or by procoagulant factors (e.g., thrombin) released from clots. 46 The absence of a correlation between FPA and creatine kinase plasma levels or ischemic time is not in favor of the first hypothesis, and the very early FPA increase (30 minutes after streptokinase treatment28) does not support the second one. Thrombolysis itself or the thrombolytic drug may, by yet unknown feedback mechanisms, paradoxically promote a secondary prothrombotic reaction that reestablishes a disturbed equilibrium. Streptokinase has previously activated platelets in a dose-and plasminogen-dependent manner. 47 Finally, t-PA itself releases fibrinopeptides (mainly FPB) from fibrinogen, as recently shown in vitro.48 FPA, therefore, may not be a specific marker of thrombin activity. But, compared with FPA levels measured in vitro and in patients with pulmonary embolism under rt-PA and heparin treatment (mean 5.9 nM48), our FPA levels were not only higher under rt-PA treatment (93+86 ng/ml), but fell under heparin treatment (in patients without reocclusion) to levels that may indeed represent this t-PA action on fibrinogen, considering the further decrease after completion of rt-PA infusion. Thus, although rt-PA itself may induce a minor additional FPA increase, the fluctuation of FPA levels measured in our patients under rt-PA or heparin infusion or both may be interpreted as an index of intravascular thrombin activity. Moreover, no evidence exists that fibrin originating from thrombin or thrombin/ t-PA activity would behave differently with regard to thrombosis.
A substantial fibrinogen depletion under rt-PA infusion was detected in most of our patients. However, although commonly used during thrombolysis, the Clauss method may give spuriously low fibrinogen values by defective fibrin polymerization in presence of high levels of fibrin(ogen) degradation products. 49, 50 Postlytic Fibrinopeptide A and Reocclusion
In patients with successful rt-PA-induced reperfusion and coronary patency 11.7+6.9 days later, FPA levels fell abruptly below the admission value within 30 minutes after heparinization and did not exceed a critical level of 5 ng/ml for the next 12 (and, with a few exceptions, up to 24) hours under continued anticoagulation (see Figure 1) . The same is probably true for patients without initial reperfusion. A slight FPA increase at 24 hours (with 3 of 25 values >5 ng/ml) was observed in most of the patients. These levels are distinctly lower than those observed after streptokinase and heparin infusion in previous studies,28 raising again the question of spurious elevation of FPA by fibrinogen degradation peptides.
Each one of our five patients with clinical and electrocardiographic evidence of recurrent severe ischemia after initial reperfusion had persistent high or reincreasing FPA levels 30 minutes after completion of thrombolytic therapy. This clinical observation and the subsequent results from angiography do not allow the drawing of a conclusive correlation between postlytic FPA plasma levels and the reocclusion risk at this point. But they strongly suggest a further evaluation of FPA as a reocclusion marker. Patients with postlytic FPA levels below 5 ng/ml, or below their own admission value, seem to be at low risk of reocclusion for several days after successful reperfusion. Postlytic FPA levels that do not fall below the admission value or increase again despite full anticoagulation with heparin indicate ongoing fibrin generation. These patients seem to be at risk of reocclusion and may need more intense heparin treatment or early angiography and angioplasty.
In a short communication,51 thrombin-antithrombin Ill-complex levels were recently postulated as a reocclusion marker after rt-PA-induced thrombolysis. This would further support our view that monitoring of circulating thrombin activity or fibrin generation could be helpful in managing patients after successful thrombolytic therapy. On the other hand, platelet aggregation has been convincingly shown to be involved in reocclusion after thrombolysis with rt-PA despite full heparinization in a canine preparation of coronary thrombosis. 52 The importance of platelet aggregation preceding rethrombosis after thrombolysis has not been examined in our patients and remains an interesting question. Conclusions FPA allows a monitoring of intravascular fibrin generation during acute myocardial infarction and thrombolytic therapy, provided blood sampling is unproblematic. Plasmin 
